The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI-antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

 
Web www.patentalert.com

< Adeno-associated viral vector-mediated delivery of DNA to cells of the liver

< Methods of inhibiting GPR-9-6 function

> Human mesenchymal progenitor cell

> Benzazepine derivatives, process for the preparation of the same and uses thereof

~ 00204